| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,500,000 |
| Market
Cap: |
1.95(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$35.77 - $65 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amphastar Pharmaceuticals is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient (API) products. Co.'s reportable segments are: finished pharmaceutical products, which manufactures, markets and distributes Primatene Mist®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs; and API, which manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
32,136 |
465,065 |
655,744 |
1,062,982 |
| Total Sell Value |
$1,503,716 |
$26,033,932 |
$35,438,128 |
$50,015,597 |
| Total People Sold |
3 |
7 |
9 |
11 |
| Total Sell Transactions |
5 |
17 |
34 |
71 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Luo Mary Z. |
COO, Chief Scientist, Chairman |
• • • |
2024-03-04 |
4 |
A |
$0.00 |
$0 |
I/I |
27,110 |
1,131,526 |
|
- |
|
| Luo Mary Z. |
COO, Chief Scientist, Chairman |
• • • |
2024-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
64,310 |
2,143,028 |
|
- |
|
| Peters William J |
CFO, EVP & TREASURER |
• • – |
2024-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
19,440 |
120,800 |
|
- |
|
| Liawatidewi Yakob |
EVP CORP ADMIN CENTER |
• • – |
2024-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
10,754 |
80,423 |
|
- |
|
| Petersen Floyd F. |
|
– • – |
2024-03-01 |
4 |
AS |
$45.60 |
$22,847 |
D/D |
(500) |
79,833 |
|
-11% |
|
| Petersen Floyd F. |
Director |
– • – |
2024-02-01 |
4 |
AS |
$53.07 |
$26,548 |
D/D |
(500) |
80,333 |
|
-23% |
|
| Zhang Jack Y. |
CEO & Chief Scientific Officer |
• • • |
2024-01-10 |
4 |
AS |
$54.32 |
$7,171,768 |
D/D |
(131,386) |
1,104,416 |
|
-25% |
|
| Zhang Jack Y. |
CEO & Chief Scientific Officer |
• • • |
2024-01-09 |
4 |
AS |
$56.70 |
$4,923,232 |
D/D |
(86,156) |
1,235,802 |
|
-28% |
|
| Zhang Jack Y. |
CEO & Chief Scientific Officer |
• • • |
2024-01-08 |
4 |
AS |
$56.98 |
$7,875,476 |
D/D |
(133,644) |
1,321,958 |
|
-31% |
|
| Petersen Floyd F. |
Director |
– • – |
2024-01-02 |
4 |
AS |
$60.56 |
$30,683 |
D/D |
(500) |
80,833 |
|
-34% |
|
| Zhou Rong |
Senior EVP, Production Center |
• – – |
2023-12-04 |
4 |
S |
$59.58 |
$209,364 |
D/D |
(3,514) |
112,420 |
|
32% |
|
| Zhou Rong |
Senior EVP, Production Center |
• – – |
2023-12-04 |
4 |
OE |
$16.19 |
$56,892 |
D/D |
3,514 |
115,934 |
|
- |
|
| Zhou Rong |
Senior EVP, Production Center |
• – – |
2023-12-01 |
4 |
S |
$58.58 |
$252,831 |
D/D |
(4,316) |
112,420 |
|
32% |
|
| Zhou Rong |
Senior EVP, Production Center |
• – – |
2023-12-01 |
4 |
OE |
$14.40 |
$62,150 |
D/D |
4,316 |
116,736 |
|
- |
|
| Petersen Floyd F. |
Director |
– • – |
2023-12-01 |
4 |
AS |
$57.24 |
$28,952 |
D/D |
(500) |
81,333 |
|
-32% |
|
| Prins Richard K |
Director |
– • – |
2023-11-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
30,895 |
|
- |
|
| Prins Richard K |
Director |
– • – |
2023-11-17 |
4 |
S |
$55.86 |
$223,446 |
D/D |
(4,000) |
31,895 |
|
22% |
|
| Peters William J |
CFO, EVP & Treasurer |
• • – |
2023-11-14 |
4 |
AS |
$54.76 |
$3,298,475 |
D/D |
(59,250) |
101,360 |
|
-23% |
|
| Peters William J |
CFO, EVP & Treasurer |
• • – |
2023-11-14 |
4 |
OE |
$13.03 |
$925,028 |
D/D |
59,250 |
160,610 |
|
- |
|
| Deflin Gayle |
Director |
– • – |
2023-11-14 |
4 |
S |
$55.45 |
$230,838 |
D/D |
(4,163) |
2,716 |
|
23% |
|
| Prins Richard K |
Director |
– • – |
2023-11-13 |
4 |
S |
$52.50 |
$262,500 |
D/D |
(5,000) |
35,895 |
|
19% |
|
| Petersen Floyd F. |
Director |
– • – |
2023-11-01 |
4 |
AS |
$45.30 |
$22,651 |
D/D |
(500) |
81,833 |
|
-4% |
|
| Petersen Floyd F. |
Director |
– • – |
2023-10-02 |
4 |
AS |
$45.78 |
$22,890 |
D/D |
(500) |
82,333 |
|
22% |
|
| Peters William J |
CFO, EVP & Treasurer |
• • – |
2023-09-06 |
4 |
AS |
$51.75 |
$3,143,195 |
D/D |
(60,743) |
101,360 |
|
7% |
|
| Peters William J |
CFO, EVP & Treasurer |
• • – |
2023-09-06 |
4 |
OE |
$13.03 |
$956,795 |
D/D |
56,500 |
162,103 |
|
- |
|
954 Records found
|
|
Page 2 of 39 |
|
|
0.28 (0.69%) 
